Kura Oncology (KURA) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a hold rating in a report issued on Thursday.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

How to Become a New Pot Stock Millionaire

A number of other analysts have also recently weighed in on the company. Cann restated a buy rating and issued a $30.00 price target on shares of Kura Oncology in a research note on Friday, February 16th. BidaskClub upgraded Kura Oncology from a hold rating to a buy rating in a research note on Wednesday, January 24th. Citigroup set a $28.00 price target on Kura Oncology and gave the company a buy rating in a research note on Friday, February 16th. Wedbush started coverage on Kura Oncology in a research note on Tuesday, December 26th. They issued a buy rating and a $19.00 price target on the stock. Finally, Oppenheimer set a $18.00 price target on Kura Oncology and gave the company a buy rating in a research note on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Kura Oncology presently has an average rating of Buy and a consensus target price of $22.50.

Shares of Kura Oncology stock opened at $18.45 on Thursday. Kura Oncology has a 52 week low of $5.90 and a 52 week high of $24.02. The company has a quick ratio of 9.44, a current ratio of 9.44 and a debt-to-equity ratio of 0.07.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Monday, March 12th. The company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.01). research analysts predict that Kura Oncology will post -1.43 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. New York State Common Retirement Fund acquired a new stake in shares of Kura Oncology during the second quarter worth about $142,000. MetLife Investment Advisors LLC acquired a new stake in shares of Kura Oncology during the fourth quarter worth about $155,000. American International Group Inc. increased its position in shares of Kura Oncology by 42.0% during the fourth quarter. American International Group Inc. now owns 13,574 shares of the company’s stock worth $208,000 after purchasing an additional 4,012 shares in the last quarter. California State Teachers Retirement System acquired a new stake in shares of Kura Oncology during the second quarter worth about $235,000. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of Kura Oncology during the fourth quarter worth about $392,000. Institutional investors and hedge funds own 58.56% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Kura Oncology (KURA) Downgraded by Zacks Investment Research” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3299506/kura-oncology-kura-downgraded-by-zacks-investment-research.html.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

AutoZone  Coverage Initiated by Analysts at Wells Fargo
AutoZone Coverage Initiated by Analysts at Wells Fargo
Textainer Group  Now Covered by Analysts at Compass Point
Textainer Group Now Covered by Analysts at Compass Point
Owens-Illinois  Releases Q2 Earnings Guidance
Owens-Illinois Releases Q2 Earnings Guidance
Sanmina  Posts Quarterly  Earnings Results, Beats Estimates By $0.05 EPS
Sanmina Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS
ConforMIS  Earns News Impact Score of 0.18
ConforMIS Earns News Impact Score of 0.18
Marchex  Getting Somewhat Positive News Coverage, Report Shows
Marchex Getting Somewhat Positive News Coverage, Report Shows


© 2006-2018 Ticker Report. Google+.